Potenzielle Wirkstoffe identifizieren, testen oder optimieren: PROvendis bietet attraktive Technologien aus dem pharmazeutischen Bereich zur Lizenzierung, zum Kauf oder für Entwicklungskooperationen an.
Nehmen Sie Kontakt mit uns auf! Weitere Ansprechpartner*innen finden Sie auch in jedem Technologieangebot.
Bidirectional Nanobody System For Fibrinolysis
A novel system of dual-functioning nanobodies, designed to enable precise and reversible control of thrombolytic activity. One set of nanobodies accelerate clot lysis, closely simulating in vivo thrombolysis while the other set of nanobodies acts as anti-fibrinolytics. The system represents a unique safety mechanism, allowing immediate and controlled cessation of fibrinolysis in the event of bleeding complications.
Viskositätsstabile Polysaccharide
Die neuen Xanthanvarianten (Chimäre Gt1 und insbesondere Chimäre GumK) zeigen im Vergleich zur ∆gumI-Variante eine gänzlich andere Temperaturstabilität der Viskosität und Funktionalität des erhaltenen EPS.
First Plant-Based Dual-Action Candidate
A plant-based compound prevents neuropathic pain and neuropathy-related sleep-wake disorders. Targeting receptors are the Kappa-Opioid-receptor and Serotonin-Transporter. The results promise a plausible dual analgesic–sedative rationale aligned with clinical standards for neuropathic pain management.
Feststofferzeugung
Herstellung von Kristallen aus einer Lösung durch ein modifiziertes Sprühtrocknungsverfahren, bei dem die Lösung mit einem verdichteten Gas vermischt wird. Die Lösung wird dann entspannt, wodurch ein Schaum entsteht. Die Blasengrenzflächen sind ideale Keimbildungsstellen zur Kristallisation und zur Abtrennung des Lösungsmittels.
SelectCells
Extremely mild, selective and efficient technique for separating cells based on temperature-sensitive polymer coating, particularly stem and iPS cells.
Treatment of ocular hypertension
Increased intraocular pressure (IOP), also known as ocular hypertension, is widely associated with open-angle and narrow-angle glaucoma. These servere eye diseases may lead to blindness. Current therapeutic approaches use carbonic anhydrase inhibitors (CA Inhibitors), beta blockers, alpha2-receptor agonists, prostaglandins and cholinergics.
Artificial Interferons
The invention comprises IFNα2 mutants achieved by designing an IFNα2 with amino acids from IFNα14, which significantly improved their antiviral activity against chronic HBV. As IFNα14 is not suitable for use as a drug, unlike IFNα2, and considering that the IFNα2 mutant is almost as effective as IFNα14, it appears the IFNα2 mutant could be a viable option for clinical application.
Click-Mass Spectrometry of lipids
Aberrations in fatty acid metabolism are associated with pathological states and have become a focus of current research, particularly due to the interest in metabolic overload diseases.
HTRA inhibitors
High Temperature Requirement A (HTRA) proteins are serine proteases of the S1 family (trypsin/chymotrypsin-like). HTRA1 is supposed to play a role in macular degeneration, and HTRA2 has been associated with cell death in reperfusion-ischemia.
Novel Anti-Tuberculosis Compounds
The resurgence of tuberculosis, caused primarily by Mycobacterium tuberculosis (Mtb), and the appearance of multi‐drug and extensively drug resistant Mtb strains strengthen the need for new drugs with alternative modes of action.
CEACAM1 antibodies for anti-viral therapy
Cytotoxic CD8-positive T cells constitute the crucial leukocyte subpopulation for a cellular response against viral infection.
Parthenolide and its derivatives for use in the treatment of axonal damage
Peripheral nerve damage is a common cause of considerable functional morbidity, and healthcare expenditure.
Corallopyronin A as antifilarial drug
The novel anthelmintic natural compound Corallopyronin A (CorA) adresses the heartworm disease in dogs caused by the infection of Dirofilaria parasites (D. immitis and D. repens). The invention is in a late pre-clinical stage: Data are available concerning toxicology and pharmacology. A formulation of CorA is also under development. A production process of CorA has been set up.
Druggable oncogenic fusions
Cancer patients frequently bear therapeutically relevant genome alteration. For instance, lung adenocarcinomas of patients that have never smoked carry genome alterations affecting kinases, such as EGFR mutations and translocations affecting ALK, ROS1 and RET genes.
Exosomes
Exosomes are nano-sized, secreted cell organelles that are released by a huge variety of different cell species, including mesenchymal stem cells (MSCs). Containing a combination of lipids and proteins as well as RNAs, exosomes participate in intercellular communication processes.
Corallopyronin A as antifilarial drug
The novel anthelmintic natural compound Corallopyronin A (CorA) adresses Elephantiasis and River blindness caused by the infection with filarial nematodes (mainly by Wuchereria bancrofti, Brugia malayi, Brugia timori and Onchocerca volvulus). The invention is in a late pre-clinical stage: Data are available concerning toxicology and pharmacology. A formulation of CorA is also under development. A production process of CorA has been set up.
Circular RNA
Scientists of the University Hospital Bonn and Stanford University have discovered that mammalian IRES-like sequences can overcome the efficiency limitations of eukaryotic translation initiation in circular RNA therapeutics.
Mouse models for haematopoiesis and deafness
Mouse models for studying hematopoietic differentiation without severe systemic effects. Mouse models suited for research focusing on erythroid and megakaryocytic lineages. Mouse models for studying defects in granulocyte development and inner ear hair cell biology, in particular deafness. Mouse models with GFP reporter gene additionally available.
GSDMD VHHs prevent pyroptosis
Single domain antibodies (sdAbs) against GSDMD prevent pyroptosis, GSDMD pore formation and IL-1β release. sdAbs act intra and extracellularly.
Supplements for T Cell-Based Immunotherapy
Optimized conceot for the activation of CAR T cells and prevention of exhaustion in the treatment of cancer.
Synthetic Cytokine Receptors
Synthetic cytokine receptors (SyCyRs) enable defined background-free cellular responses through addition of synthetic ligands. The system allows the engineering of highly specific amplification or eradication switches for recombinant cells.
Chromosomal rearrangements in lung cancer
The invention allows to predict tumor responsiveness to FGFR inhibitor treatment, hence, it can serve as a diagnostic tool to guide personalized precision medicine in cancer treatment.
Novel therapy for Metachromatic Leukodystrophy
The technology relates to a variant of the enzyme arylsulphatase A characterised by increased blood-brain barrier permeability, catalytic activity and half-life, and which is suitable for the treatment of metachromatic leukodystrophy by an enzyme replacement therapy.
New Cryptophycins for ADC and SMDC
The present invention combines new synthetic ways to new Cryptophycin derivatives with alternative conjugation possibilites and pico-molar cytotoxicies, for ADC and SMDC synthesis.
Nano-BioTransporter
Cancer is one of the main causes of death worldwide. One of the newer therapeutic approaches is photodynamic therapy (PDT), a treatment that uses a photosensitizing chemical substance, a particular type of light and oxygen.
Cholinergic activity enhancer
Acetylcholine (ACh) is an essential neurotransmitter with a major function in the central and peripheral nervous system. Furthermore, ACh plays a crucial role in the autonomic nervous system stimulating preganglionic parasympathetic and sympathetic nerve fibres and postganglionic parasympathetic neurons.
Spray freeze-drying
Spray freeze-drying combines the advantageous properties of the well-established techniques spray drying and freeze-drying.
MRGPRX4 Receptor Agonists and Antagonists
G protein-coupled receptors (GPCRs) are the largest group of membrane receptor proteins and represent the most successful targets of drug therapy.
MRGX2 Receptor Antagonists
G protein-coupled receptors (GPCRs) are the largest group of membrane receptor proteins and represent the most successful targets of drug therapy.
NMDAR Antagonists as new Antidiabetic Medication
According to the International Diabetes Federation (IDF), diabetes affects close to 400 million people worldwide and caused 500 billion Euros in health expenditure in 2013.